Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs.

Literature DB >> 15941837

Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs.

W W Bolten¹.
1. wbolten@em.uni-frankfurt.de

Abstract

Treatment of pain in rheumatoid arthritis must take into account the gastrointestinal and cardiovascular risk of individual patients. Adequate results are not yet available, and until they are, treatment recommendations must take into account, not only the more favourable gastrointestinal risk profile of selective COX-2 inhibitors, but also the potential atherothrombotic risk of any NSAID or selective COX-2 inhibitor treatment.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2005 PMID： 15941837 PMCID： PMC1797984 DOI： 10.1136/ard.2005.036269

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

36 in total

1. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors: Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321

2. Coxibs and cardiovascular disease.

Authors: Garret A Fitzgerald
Journal: N Engl J Med Date: 2004-10-06 Impact factor: 91.245

3. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

Authors: J P Kelly; D W Kaufman; J M Jurgelon; J Sheehan; R S Koff; S Shapiro
Journal: Lancet Date: 1996-11-23 Impact factor: 79.321

4. A randomized trial of aspirin to prevent colorectal adenomas.

Authors: John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk
Journal: N Engl J Med Date: 2003-03-06 Impact factor: 91.245

5. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

Authors: Muhammad Mamdani; Paula Rochon; David N Juurlink; Geoffrey M Anderson; Alex Kopp; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal: Arch Intern Med Date: 2003-02-24

6. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors:
Journal: BMJ Date: 1994-01-08

7. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Authors: Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Patrice Matchaba; Alberto Gimona; Christopher J Hawkey
Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321

8. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin.

Authors: M Lecomte; O Laneuville; C Ji; D L DeWitt; W L Smith
Journal: J Biol Chem Date: 1994-05-06 Impact factor: 5.157

9. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.

Authors: Loren Laine; Eric S Maller; Chang Yu; Hui Quan; Thomas Simon
Journal: Gastroenterology Date: 2004-08 Impact factor: 22.682

10. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.

Authors: Marta L Capone; Stefania Tacconelli; Maria G Sciulli; Marilena Grana; Emanuela Ricciotti; Pietro Minuz; Patrizia Di Gregorio; Gabriele Merciaro; Carlo Patrono; Paola Patrignani
Journal: Circulation Date: 2004-03-22 Impact factor: 29.690

11 in total

1. Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors: Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal: Ther Adv Musculoskelet Dis Date: 2013-08 Impact factor: 5.346

Review 2. Issues in the treatment of ankylosing spondylitis with non-steroidal anti-inflammatory drugs.

Authors: Sjef van der Linden
Journal: Wien Med Wochenschr Date: 2008

Review 3. The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis.

Authors: Mazen Elyan; Muhammad Asim Khan
Journal: Curr Rheumatol Rep Date: 2006-08 Impact factor: 4.592

4. Prevention of stroke in rheumatoid arthritis.

Authors: Namrata Dhillon; Kimberly Liang
Journal: Curr Treat Options Neurol Date: 2015-07 Impact factor: 3.598

Review 5. Colchicine for secondary prevention of cardiovascular disease.

Authors: Stefan M Nidorf; John W Eikelboom; Peter L Thompson
Journal: Curr Atheroscler Rep Date: 2014-03 Impact factor: 5.113

Review 6. Inflammation and shoulder pain--a perspective on rotator cuff disease, adhesive capsulitis, and osteoarthritis: conservative treatment.

Authors: Bernardino Saccomanni
Journal: Clin Rheumatol Date: 2009-02-18 Impact factor: 2.980